Advancing Cancer Research in Sub-Saharan Africa
This grants program, focused initially on Uganda and Kenya, will serve as a pilot initiative to advancing clinical cancer research for rapid impact on patient outcomes in sub-Saharan Africa; and to enhancing capacities to empower applicants from these countries to effectively compete as leading investigators for global research opportunities in the future. Lessons learned from this pilot will serve as a basis to expand this program in subsequent years to encompass additional sub-Saharan African countries.
Supported Research Approaches, and Permissible Technical Foci:
Areas of cancer intervention that will be supported under this program include early detection and diagnosis, treatment, delivery of care, and palliative care.
- Applications focused on breast, colorectal, esophageal, or hematological cancers are strongly encouraged. Applications focused on cancers largely supported under global infectious disease investments (such as cervical or Kaposi Sarcoma) should NOT be submitted.
- RTFCCR is particularly interested in research that can lead to better patient outcomes in the near-term future, including quality of life; with an emphasis on outcomes identified in partnership with patients.
- Implementation research, as well as clinical trials, both bio-medical and behavioral, will be supported under this RFP. Proposals for basic and/or translational research are NOT invited and will NOT be reviewed.
RTFCCR has a particular interest in drug-repurposing, therapy de-escalation, and palliative care, as well as application of technology to expand capacity in-country for detection and/or treatment. Regardless of the specific focus or approach, applicants must include Patients as Partners in their efforts to be eligible for funding under this RFP.
Timeline & Quick Facts
Stage I: Needs Assessment and Planning Grants
October 1, 2023: Request for Proposals (RFP) Issued
December 1, 2023: Applications due
January 19, 2024 Grantees Selected and Awards Issued
December 1, 2024: Final Reports Due
Award Type: Fixed amount, $20,000, deliverable-based.
Stage II: Implementation Grants for Clinical Cancer Research with Patients as Partners
January 17, 2025: Stage I grantees invited to apply based on Stage I outcomes
March 2, 2025: Full Research Applications due
May 2025: Grantees Selected and Awards Issued
Quarterly from Date of Award: Technical & Financial Reporting
Period of Performance: 24 to 36 months
Award Type: Incremental funding tied to milestones, up to $250,000.